Immunomagnetic Depletion of Heme-Laden Microparticles in Sickle Cell Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective predictive tools and therapeutic strategies for managing vaso-occlusive crises and vascular complications in sickle cell disease, with limited understanding of the disease's pathophysiology and no specific drugs to prevent or treat these crises, leading to significant healthcare burdens.
Innovation Solution
A method involving the determination of cell microparticle levels and heme/hemoglobin content in blood samples to assess the risk of vaso-occlusive crises, with the goal of depleting heme- and hemoglobin-laden microparticles to prevent vascular injury and crises.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydroxy-urea treatment is prescribed to reduce hemolysis and sickle cell formation, then the frequency of vaso-occlusive crises may be reduced, but the treatment is only effective in about 40% of patients and carries presumptions of carcinogenesis in the long term
Solution Approach 1:
The patent extracts and removes harmful microparticles containing heme and hemoglobin from the patient's blood through immunomagnetic separation. This directly eliminates the toxic substances that cause vascular injury and vaso-occlusive crises, rather than relying on drugs that only reduce production of these particles. The method removes the actual harmful agents (microparticles) from circulation, providing a more direct and potentially safer therapeutic approach.
Solution Approach 2:
The patent uses immunomagnetic beads as an intermediary to selectively bind and remove microparticles from blood. These magnetic beads coated with anti-CD47 antibodies act as mediators that specifically capture harmful microparticles without affecting healthy cells. This intermediary approach enables precise removal of toxic substances while avoiding the systemic side effects of pharmacological treatments like hydroxy-urea.
2Reliability
If blood transfusion is performed to treat severe vaso-occlusive crises, then the crises can be managed, but patients are exposed to viral infection, secondary hemochromatosis, and transplantation complications
Solution Approach 1:
The patent extracts harmful microparticles from the patient's own blood, creating a form of autologous therapy that eliminates the need for allogeneic blood transfusions. By removing the toxic substances (heme- and hemoglobin-laden microparticles) that trigger crises, the treatment addresses the root cause without introducing external blood products, thereby avoiding viral infections, hemochromatosis, and transplantation complications associated with traditional transfusion therapy.
Solution Approach 2:
The patent converts the patient's own blood, which contains harmful microparticles, into a therapeutic resource. By processing the patient's autologous blood to remove toxic microparticles and returning the purified components, the treatment transforms a potentially harmful substance into a safe therapeutic intervention, eliminating the need for external blood products and their associated risks.
3Loss of time
If clinical indicators are used to identify patients at risk for vaso-occlusive crises, then management can be guided, but these indicators are generally identified only when the crisis has begun or complications are already advanced
Solution Approach 1:
The patent measures microparticle levels and heme/hemoglobin content in the patient's blood before a crisis occurs, enabling early identification of patients at high risk for vaso-occlusive crises. This preliminary assessment allows clinicians to initiate preventive treatments or monitor at-risk patients more closely before actual crises or complications develop, overcoming the limitation of traditional indicators that only become apparent after crisis onset.
Solution Approach 2:
The patent replaces traditional clinical indicators (which rely on observing crisis symptoms) with a biochemical measurement system that directly quantifies the actual toxic substances (microparticles, heme, hemoglobin) in the blood. This substitution provides a more precise and earlier detection method, allowing risk assessment based on the presence and concentration of harmful substances rather than waiting for clinical manifestations of crisis.
4Reliability
If the focus remains on blocking RBC remodeling to prevent anemia, then anemia can be managed, but the intricate combination of circulating and cardiovascular factors contributing to vaso-occlusive crises and vascular injury is not addressed
Solution Approach 1:
The patent extracts and removes the harmful microparticles, heme, and hemoglobin from the patient's blood that cause vascular injury and vaso-occlusive crises. This directly addresses the cardiovascular and circulating factors that contribute to crises, moving beyond merely preventing anemia by blocking RBC remodeling. The method eliminates the actual toxic substances that damage blood vessels and trigger occlusion events.
Solution Approach 2:
The patent uses immunomagnetic separation as an intermediary mechanism to selectively remove microparticles and their toxic contents (heme and hemoglobin) from circulation. This intermediary approach specifically targets the harmful circulating factors that cause vascular injury, providing a focused therapeutic strategy that addresses both anemia and vaso-occlusive crises by eliminating the root toxic substances rather than merely preventing their formation.
Data Source
Figure 1~2A
Figure 2B~3A
Figure 3B~4A
AI summary
The present invention relates to methods for determining the risk of severe complications in hemolytic diseases. The present invention relates to a method for determining whether a patient suffering from sickle cell disease is at risk for a vaso-occlusive crisis comprising the steps consisting of i) determining the level of cell microparticles in a blood sample obtained from said patient and ii) determining the level of heme and/or hemoglobin contained in said cell microparticles. The present invention also relates to a method for a method the severe complication in hemolytic diseases comprising the steps consisting of i) determining the level of cell microparticles in a blood sample obtained from said patient and ii) determining the level of heme and/or hemoglobin contained in said cell microparticles. The present invention also relates to a method for preventing a vaso-occlusive crisis in a patient afflicted with by sickle cell disease comprising depleting the blood-borne microparticles laden in heme and hemoglobin from the blood of said patient.